Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events
- 161 Downloads
We aimed to evaluate the additional information of 18 fluorodeoxyglucose (FDG) arterial uptake with respect to other conventional cardiovascular risk factors and arterial calcifications in patients with stable cancer.
Methods and Results
We compared the rate of cardiovascular events in 2 groups of patients with (n=45) and without (n=56) enhanced arterial 18FDG uptake, matched for the main clinical parameters. The extent and intensity of 18FDG uptake were quantified. A calcification index was also determined. About one third of the selected patients had a history of cardiovascular events and thus could be defined as “vulnerable patients.” Old cardiovascular events (>6 months before or after positron emission tomography [PET]) and recent cardiovascular events (<6 months before or after PET) were significantly more frequent in the high-FDG uptake group than in the low-FDG uptake group (48% vs 15%, respectively [P=.0006], and 30% vs 1.8%, respectively [P=.0002]). The extent of 18FDG arterial uptake was the unique factor significantly related to the occurrence of a recent event by either logistic regression or discriminant analysis (P=.004 for all). Conversely, calcium index was the single factor related to old events (P=.004 and P=.002, respectively).
Extensive arterial 18FDG uptake might be an indicator of an evolving atherosclerotic process and should be mentioned in PET/computed tomography reports.
Key WordsFluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography scan atherosclerosis cardiovascular risk
Unable to display preview. Download preview PDF.
- 13.Davies JR, Rudd JHF, Fryer T, Graves MJ, Clark JC, Kirkpatrick PJ, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 2005;36:2642–7.PubMedCrossRefGoogle Scholar
- 14.Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the Association and the American College of Cardiology. J Am Coll Cardiol 2001;38:1581–3.PubMedCrossRefGoogle Scholar
- 22.Pyorala K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004;27:1735–40.PubMedCrossRefGoogle Scholar